O
INZY

OrbiMed’s Inozyme Pharma INZY Stock Holding History

OrbiMed’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-526,600
Closed -$3.59M – 154
2021
Q4 		$3.59M Buy
526,600
+232,600
+79% +$2.01M 0.05% 142
2021
Q3 		$3.41M Buy
294,000
+105,296
+56% +$1.64M 0.04% 161
2021
Q2 		$3.22M Buy
+188,704
New +$3.28M 0.03% 153
2021
Q1 		– Sell
-400,400
Closed -$8.26M – 171
2020
Q4 		$8.26M Hold
400,400
– – 0.07% 127
2020
Q3 		$10.5M Buy
+400,400
New +$9.95M 0.13% 109

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OrbiMed's INZY Position: Q1 2022 in Review

OrbiMed sold out of Inozyme Pharma (INZY) in Q1 2022, closing a stake of 526,600 shares — an estimated $3.59M sold.

OrbiMed first reported a position in INZY in Q3 2020 and held it in 5 quarters. The position peaked at $10.5M in Q3 2020. 50 funds tracked by Wall St. Rank hold INZY as of Q1 2022.

  • OrbiMed reported no remaining Inozyme Pharma position as of Q1 2022 after selling out during the quarter.
  • OrbiMed sold 526,600 Inozyme Pharma shares in Q1 2022, an estimated $3.59M.
  • OrbiMed first reported a position in Inozyme Pharma in Q3 2020 and held it in 5 quarters.
  • OrbiMed's Inozyme Pharma position peaked at $10.5M in Q3 2020.
  • 50 funds tracked by Wall St. Rank held Inozyme Pharma as of Q1 2022.

Based on OrbiMed's 13F filing for Q1 2022, filed 16 May 2022.